A detailed history of Commodore Capital LP transactions in Celcuity Inc. stock. As of the latest transaction made, Commodore Capital LP holds 1,522,332 shares of CELC stock, worth $18.9 Million. This represents 1.93% of its overall portfolio holdings.

Number of Shares
1,522,332
Previous 1,464,105 3.98%
Holding current value
$18.9 Million
Previous $24 Million 5.36%
% of portfolio
1.93%
Previous 2.15%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.98 - $19.15 $814,013 - $1.12 Million
58,227 Added 3.98%
1,522,332 $22.7 Million
Q2 2024

Aug 14, 2024

SELL
$14.1 - $20.78 $1.3 Million - $1.91 Million
-91,849 Reduced 5.9%
1,464,105 $24 Million
Q1 2024

May 15, 2024

SELL
$13.74 - $21.6 $2.73 Million - $4.29 Million
-198,750 Reduced 11.33%
1,555,954 $33.6 Million
Q4 2023

Feb 14, 2024

BUY
$8.7 - $15.02 $526,898 - $909,656
60,563 Added 3.57%
1,754,704 $25.6 Million
Q3 2023

Nov 14, 2023

BUY
$8.96 - $10.75 $2.24 Million - $2.69 Million
250,000 Added 17.31%
1,694,141 $15.5 Million
Q2 2023

Aug 14, 2023

BUY
$9.39 - $12.18 $501,134 - $650,034
53,369 Added 3.84%
1,444,141 $15.9 Million
Q1 2023

May 15, 2023

BUY
$9.4 - $12.82 $590,508 - $805,352
62,820 Added 4.73%
1,390,772 $14.3 Million
Q4 2022

Feb 14, 2023

BUY
$7.55 - $14.01 $3.08 Million - $5.71 Million
407,488 Added 44.27%
1,327,952 $18.6 Million
Q3 2021

Nov 15, 2021

BUY
$17.35 - $24.87 $858,772 - $1.23 Million
49,497 Added 5.68%
920,464 $16.6 Million
Q2 2021

Aug 16, 2021

BUY
$14.25 - $30.93 $12.4 Million - $26.9 Million
870,967 New
870,967 $20.9 Million

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $185M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Commodore Capital LP Portfolio

Follow Commodore Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Commodore Capital LP with notifications on news.